Status and phase
Conditions
Treatments
About
This study will compare the low-sodium/low-fat DASH (Dietary Approaches to Stop Hypertension) diet with a very low-carbohydrate diet, helping us to better understand how two different dietary approaches may help participants control their blood pressure, lose weight, and reduce their blood glucose.
Full description
Adults with overweight or obesity, hypertension, and prediabetes or type 2 diabetes are at a high risk of adverse health outcomes including stroke, renal disease, myocardial infarction, and premature death. Evidence suggests that the first-line treatment for adults with this triple burden should be a comprehensive diet and lifestyle intervention.
However, experts disagree about which diet should be recommended. The Dietary Approaches to Stop Hypertension (DASH) diet, a lower fat diet, is the de facto diet for adults with hypertension. A very low-carbohydrate (VLC) diet, a higher fat diet, is becoming the de facto diet for weight and glycemic control. In addition, a VLC diet may reduce blood pressure through weight loss and its impact on insulin (which alters renal sodium transport and leads to diuresis). Given that these two diets, DASH and very low-carbohydrate, are extremely promising options for this population, and the fact that they have never been compared in this population or any other, this comparison is strongly warranted.
The investigators propose to use an interprofessional team (with expertise in nursing, psychology, medicine, policy, nutrition, pharmacy, and behavioral interventions) to conduct a comparative effectiveness trial of two different diets for adults with this triple burden. The HERO Study (Hypertension, Diabetes, and Obesity Education Research Online) will compare the health effects of the DASH and VLC diets.
The investigators propose one aim:
Test the feasibility, acceptability, and preliminary comparative efficacy of the interventions. The investigators will randomize 140 adults with this triple burden to the DASH or VLC versions of the 4-month intervention. Outcome measures include intervention feasibility (recruitment and retention); acceptability (satisfaction with the intervention); and preliminary comparative efficacy as determined by changes in our primary outcome (systolic blood pressure), as well as exploratory secondary outcomes (weight, glycemic control).
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
BMI of 25-50
Diagnosis pre-hypertension or hypertension (within the past 6 months) and current resting systolic blood pressure > 130 mmHg.
Diagnosis of either prediabetes or type 2 diabetes, defined as:
Aged 21-70 years old
Access to the internet and text messaging
Ability to engage in light physical activity
Sufficient control over their food intake to adhere to study diets
Willingness to regularly monitor blood pressure, glucose, dietary intake, and body weight over 4-month trial
Participation in the trial approved by primary care provider, along with agreement to work with the participant and our research team to manage medication changes
Exclusion criteria
Non-English speaking
Current use of insulin, Dilantin, lithium, and warfarin
Inability to complete baseline measurements
Severe renal or hepatic insufficiency
Cardiovascular dysfunction, including diagnosis of:
Uncontrolled psychiatric disorder
Consumes >30 alcoholic drinks per week
Currently undergoing chemotherapy
Pregnant or planning to get pregnant in the next 12 months
Breastfeeding or less than 6 months' post-partum
Planned weight loss surgery or similar surgery performed previously
Vegan or vegetarian
Currently enrolled in a weight loss program or take weight loss supplements (that are not willing to be stopped before enrolling)
Expecting to move out of the area within 12 months
Any other medical condition that may make either diet dangerous as determined by the study medical team.
Primary purpose
Allocation
Interventional model
Masking
94 participants in 4 patient groups
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal